Alex Dale, Author at Labiotech.eu

About

A former journalist intern at Labiotech, Alex now works as a copywriter in healthcare advertising. When he’s not writing, he enjoys playing sports and long-distance cycling.

Articles by Alex Dale

News and Trends 27 Feb 2018

DBV Technologies’ Milk Allergy Patch Helps Kids in a Phase II Trial

DBV Technologies’ candidate could be the first treatment for allergies to cow milk after its Viaskin Milk skin patch achieved positive Phase II results. DBV Technologies is developing a skin patch, Viaskin, as an immunotherapy for the treatment peanut, egg, and milk allergies. In a Phase II study, Viaskin Milk has desensitized children between the […]

February 27, 2018 - 3 minutesmins - By Alex Dale

multiple sclerosis antibody CIDP geneuro 1

News and Trends 26 Feb 2018

This Multiple Sclerosis Drug Could Help to Fight Another Autoimmune Disease

The FDA has awarded Orphan Drug Designation to GeNeuro’s antibody for the treatment of a rare autoimmune disease following promising Phase IIb results in multiple sclerosis patients. GeNeuro develops therapies targeting factors encoded by human endogenous retroviruses that are implicated in neurological and autoimmune disorders. The biotech’s drug, GNbAC1, which is being developed for multiple […]

February 26, 2018 - 2 minutesmins - By Alex Dale

News and Trends 26 Feb 2018

This Oral Vaccine for Typhoid Raises €8M from International Investors

Prokarium has raised $10M (€8M) from Saudi, Swedish and Korean investors to support the clinical development of its oral vaccines for infectious diseases like typhoid. Since its foundation in 2012, Prokarium has been working on oral vaccines and it has developed a delivery platform that can be applied to any antigen used for vaccination. The biotech has […]

February 26, 2018 - 3 minutesmins - By Alex Dale

Interview 26 Feb 2018

This Biotech Could Replace Opioids with Safe and Effective Pain Relief for Osteoarthritis

The use of opioids and non-steroidal anti-inflammatory drugs (NSAIDs) is a massive public health issue. I spoke with Simon Westbrook, CEO of Levicept, whose new approach to pain relief, which is being tested for osteoarthritis, could be a game-changer. Back in September, a couple of weeks into my time at Labiotech, I got the chance […]

February 26, 2018 - 9 minutesmins - By Alex Dale

News and Trends 23 Feb 2018

Crack Open the Champagne, AiCuris’ Antiviral Launched in Germany

Update (23/02/2018): Merck Sharp & Dohme (MSD), licensee of AiCuris, has launched letermovir in Germany under the trade name Prevymis. The antiviral drug will be available to patients undergoing a hematopoietic stem cell transplant (HSCT) to prevent reactivation of latent human cytomegalovirus (CMV), which can prove lethal in the weakened state of this patients. Update (31/01/2018): […]

February 23, 2018 - 3 minutesmins - By Alex Dale

News and Trends 22 Feb 2018

GW Pharma’s Latest Cannabinoid Drug Pegged Back by a Placebo in Phase II

One of GW Pharma’s cannabinoid drugs for epilepsy has suffered a set back in a Phase IIa trial as a placebo matched its capacity to reduce the frequency of focal seizures. GW Pharma wants to use cannabinoid drugs to treat conditions like autism and epilepsy. However, one of its drug candidates, GWP42006, has slipped up in a Phase […]

February 22, 2018 - 2 minutesmins - By Alex Dale

News and Trends 22 Feb 2018

Bacteria-Killing Viruses Could Stop You From Getting Food Poisoning

A group of Finnish scientists has demonstrated that phage could be used to prevent food poisoning by killing dangerous foodborne pathogens like Yersinia enterocolitica. Researchers at the University of Helsinki believe that bacteria-killing viruses called phage could be more than just an alternative to antibiotics and a solution to the growing antibiotic resistance crisis. A study, published […]

February 22, 2018 - 3 minutesmins - By Alex Dale

hiv treatment immunologik christian setz 1

Interview 22 Feb 2018

Could a New Approach Help Us to Overcome Resistance to HIV Treatment?

Clara chatted with Christian Setz, CEO of Immunologik, to find out how the company is developing a new HIV treatment that could overcome resistance to anti-retroviral drugs. Over 36 million people are living with human immunodeficiency virus (HIV), which has led to many biotechs, including Abivax, working on better options for patients. Immunologik, a recent ‘Biotech of the Week’, is […]

February 22, 2018 - 4 minutesmins - By Alex Dale

News and Trends 21 Feb 2018

Implantation of Carmat’s Artificial Heart Begins in Denmark to Beat Low Enrolment

Carmat’s artificial heart is being tested in patients with heart failure. A hospital in Copenhagen will implant the device, which the biotech hopes will boost patient enrolment to its PIVOTAL trial. Carmat has developed the world’s most advanced fully artificial heart, which has been designed for patients suffering from end-stage biventricular heart failure. The biotech has […]

February 21, 2018 - 3 minutesmins - By Alex Dale

News and Trends 21 Feb 2018

Early Autism Diagnosis Could be Possible With New Blood and Urine Tests

The detection of damaged proteins in blood and urine tests could help to diagnose autism quicker so that children can be given appropriate treatment. Researchers at the University of Warwick have developed new blood and urine tests that detect damaged proteins, which are associated with autism spectrum disorders. The study, published in Molecular Autism, explains how […]

February 21, 2018 - 3 minutesmins - By Alex Dale

metabolic disorders chaperones gain thx 1

News and Trends 20 Feb 2018

A New Biotech Hopes to Bring Us the Next Generation of Rare Metabolic Disorder Drugs

Barcelona-based biotech, Minoryx, has spun out Gain Therapeutics to develop the next generation of drugs for rare metabolic disorders like GM1 gangliosidosis. Gain Therapeutics is a new biotech that will focus on developing new pharmacological chaperones for the treatment of rare diseases. It was set up by Minoryx, a biotech that has so far raised over €24M for […]

February 20, 2018 - 3 minutesmins - By Alex Dale

News and Trends 20 Feb 2018

This Gene Therapy for Vision Loss is Safe and Effective After Two Years

The results of a long-term follow-up suggest that GenSight’s gene therapy for Leber hereditary optic neuropathy can provide safe and effective treatment for the genetic cause of vision loss. GenSight develops gene therapies to preserve or restore vision in patients with neurodegenerative diseases of the retina. The biotech’s lead candidate is GS010, which is currently […]

February 20, 2018 - 3 minutesmins - By Alex Dale

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us